Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer

FDA grants Johnson & Johnson accelerated approval for new dual-targeted head and neck cancer therapy.

What the company is saying

Johnson & Johnson is announcing U.S. FDA accelerated approval for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as a single agent for adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) that has progressed after platinum-based chemotherapy and an anti–PD–(L)1 antibody. The company frames this as the first dual-targeted therapy in this setting, emphasizing its simultaneous targeting of EGFR and MET pathways and the unmet need in this patient population. The announcement highlights robust clinical data from the Phase 1b/2 OrigAMI-4 trial, including a 42% overall response rate and durable responses, with 56% of responders maintaining benefit for over six months. Johnson & Johnson also stresses the product's differentiated mechanism and subcutaneous administration, positioning it as an advance beyond lung cancer indications. The tone is confident, supported by expert commentary from medical and patient advocacy leaders, and the company notes that continued approval is contingent on confirmatory data from the ongoing Phase 3 OrigAMI-5 trial.

What the data suggests

The OrigAMI-4 trial enrolled 102 adults with previously treated recurrent or metastatic HNSCC, excluding HPV-associated oropharyngeal cancers. Confirmed overall response rate was 42% (95% CI, 32–52%), with 15% achieving complete responses and 28% partial responses. Among responders, 56% maintained a response for more than six months. The most common adverse reactions (≥20%) were rash (79%), fatigue (39%), nail toxicity (35%), stomatitis (32%), and edema (28%). Serious adverse reactions occurred in 39% of patients, and fatal adverse reactions in 6%, including sudden death (2%). In the OrigAMI-4 safety cohort (n=132), all-grade administration-related reactions (ARRs) occurred in 16% of patients, with 91% of these events occurring with the initial dose. In the PALOMA-3 study (n=206), all-grade ARRs occurred in 13% of patients, including 0.5% Grade 3, with 89% of ARRs occurring with the initial dose. The data shows clinically meaningful efficacy and a safety profile consistent with prior amivantamab experience. No financial data, revenue projections, or commercial uptake figures are disclosed.

Analysis

The announcement is proportionate in tone, focusing on the FDA's accelerated approval of RYBREVANT FASPRO™ for a new indication, and is supported by detailed clinical trial data (ORR, DOR, adverse event rates). The majority of claims are realised and factual, with only a single forward-looking statement regarding the requirement for confirmatory Phase 3 data for continued approval. There is no evidence of narrative inflation or exaggerated language; the release is clinical and data-driven, with no promotional overstatement of commercial or financial impact. No large capital outlay or long-dated, uncertain returns are discussed. The absence of financial metrics means the signal cannot be strong_positive, but the clinical data is robust and the regulatory milestone is real and immediate.

Risk flags

• ●Continued approval is contingent on verification of clinical benefit in the Phase 3 OrigAMI-5 trial. If confirmatory results do not support the initial findings, the indication could be withdrawn, impacting future revenue and patient access.
• ●The safety profile includes a 6% fatal adverse reaction rate and 39% serious adverse reactions, which may limit uptake or lead to additional regulatory scrutiny, especially in a heavily pretreated population.
• ●No financial or commercial data is disclosed, so the economic impact of this approval remains uncertain. Without uptake data, market penetration and revenue contribution cannot be assessed.
• ●The approval excludes HPV-associated oropharyngeal squamous cell carcinoma, limiting the eligible patient pool and potentially constraining commercial opportunity.

Bottom line

Johnson & Johnson has secured FDA accelerated approval for RYBREVANT FASPRO™ as the first dual-targeted EGFR/MET therapy for recurrent or metastatic head and neck cancer, supported by a 42% response rate and durable benefit in a heavily pretreated population. The immediate impact is regulatory and clinical, expanding the drug’s label beyond lung cancer and offering a new option for patients with limited alternatives. However, the absence of financial projections or commercial uptake data means investors cannot yet gauge the revenue impact. The approval is conditional, with continued market access dependent on positive results from the ongoing Phase 3 OrigAMI-5 trial. Safety risks are material, with a notable rate of serious and fatal adverse events. The most important takeaway is that this is a real regulatory milestone for Johnson & Johnson, but the long-term commercial and financial significance will hinge on confirmatory data and actual market adoption.

Announcement summary

(NYSE:JNJ) Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as a single agent for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherapy and an anti–PD–(L)1 antibody. The approval does not include patients with oropharyngeal squamous cell carcinoma (OPSCC) that is HPV-associated. This is the first approval of a dual-targeted therapy in this setting, targeting both EGFR and MET pathways. The approval follows FDA Breakthrough Therapy Designation in February 2026 and Priority Review designation in July 2026. The indication was granted based on clinically meaningful and durable tumor response demonstrated in the Phase 1b/2 OrigAMI-4 trial. Confirmed overall response rate (ORR) was 42 percent (95 percent CI, 32–52 percent), with complete responses in 15 percent of patients and partial responses in 28 percent, per blinded independent central review (BICR). 56 percent of responders maintained a response for more than six months (1.4+, 19.7+). Continued approval may be contingent upon verification and description of clinical benefit in the ongoing Phase 3 OrigAMI-5 confirmatory trial. RYBREVANT FASPRO™ is contraindicated in patients with known hypersensitivity to hyaluronidase or any of its excipients. Warnings and precautions include hypersensitivity and administration-related reactions, interstitial lung disease/pneumonitis, dermatologic adverse reactions, ocular toxicity, and embryo-fetal toxicity. In the OrigAMI-4 trial, the most common adverse reactions (≥20%) were rash (79%), fatigue (39%), nail toxicity (35%), stomatitis (32%), and edema (28%). Serious adverse reactions occurred in 39 percent of patients, with fatal adverse reactions in 6 percent, including sudden death (2 percent), myocardial ischemia, tumor hemorrhage, aspiration pneumonia, and ILD/pneumonitis (1 percent each). Cohort 1 of OrigAMI-4 evaluated RYBREVANT FASPRO™ as a single agent in 102 adults with previously treated recurrent or metastatic HNSCC. Patients received weight-based dosing every three weeks until disease progression or unacceptable toxicity. The primary endpoint was ORR, and the secondary endpoint was duration of response, both assessed by BICR using RECIST v1.1. RYBREVANT FASPRO™ is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme's ENHANZE® drug delivery technology. For eligible patients with HNSCC, RYBREVANT FASPRO™ may be administered every four weeks or every three weeks, according to the recommended dosing schedule. RYBREVANT FASPRO™ is also approved in multiple markets for EGFR-mutated non-small cell lung cancer (NSCLC), including exon 19 deletions, exon 21 L858R substitution mutations, and exon 20 insertion mutations. The legal manufacturer for RYBREVANT FASPRO™ and RYBREVANT® is Janssen Biotech, Inc. In PALOMA-3 (n=206), all Grade administration-related reactions (ARR) occurred in 13% of patients, including 0.5% Grade 3, with 89% of ARRs occurring with the initial dose. In OrigAMI-4 (n=132), all Grade ARRs occurred in 16% of patients, with 91% of ARRs occurring with the initial dose.

Disagree with this article?